• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 and Women’s Health

Findings from PRIORITY: Outcomes in Infants Born to Women with COVID-19

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Flaherman et al. (Clinical Infectious Diseases, 2020) report early findings from the nationwide PRegnancy CoronavIrus Outcomes RegIsTrY (PRIORITY)

METHODS:

  • Prospective cohort study (March 22 to June 22)
  • Setting
    • 100 hospitals across the US
  • Participants
    • ≥13 years who are pregnant or 6 weeks postpartum
    • Suspected or confirmed COVID-19
  • Study design
    • Data collection by phone, email or text
      • At the time of enrollment | After birth | 6 to 8 weeks after delivery
    • Infant medical records were also obtained
    • Outcomes between infants whose mothers tested positive for the virus and those whose mothers tested negative were compared

RESULTS:

  • Total of 283 infants
    • Mothers tested positive: 179 infants
      • Symptomatic mothers: 81.6%
    • Mothers tested negative: 84 infants
      • Symptomatic mothers: 63.1%
  • 17% of infants were admitted to the NICU | No differences between mothers testing positive vs negative were found for the following
    • Breathing difficulties: 11%
    • Apnea: 1.6%
  • Mothers who tested positive within 0 to 14 days of delivery vs those who tested positive >14 days were
    • More likely to delivery prematurely (p=0.0009)
      • Positive maternal test 0 to 14 days: 37.5 weeks mean GA at delivery
      • Positive maternal test >14 days:  39 weeks mean GA at delivery
    • More likely to be admitted to the NICU (p=0.04)
      • Positive maternal test 0 to 14 days prior to delivery: 26.0% NICU admission
      • Positive maternal test >14 weeks prior to delivery:  12.2% NICU admission 39 weeks
  • Birth defects
    • Positive maternal test: 2 infants with multiple anomalies
    • Negative maternal test: 1 infant with multiple anomalies
  • Through 6 to 8 weeks of age
    • No pneumonia or lower respiratory tract infections were reported
    • 2 infants born to positive mothers also tested positive (1.1%)
  • No infants were re-hospitalization

CONCLUSION:

  • In the US PRIORITY registry, adverse outcomes (preterm birth, NICU admission, respiratory disease) in infants did not differ between mothers who tested positive vs those who tested negative
  • Overall, infants had minimal symptoms with a SARS-CoV-2 incidence rate of approximately 1%

The authors state

Overall, PRIORITY’s initial findings regarding infant health are reassuring

Further investigation with longer follow up periods and larger sample sizes will be needed to make a definitive determination of the risk of vertical transmission

Learn More – Primary Sources:

Infant Outcomes Following Maternal Infection with SARS-CoV-2: First Report from the PRIORITY Study

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 and Women’s Health Posts
Next >

Related ObG Topics:

Neonatal Infection: COVID-19 and Risk for Vertical Transmission
AAP Recommendations: L&D Guidance and Management of Infants Born to COVID-19 Positive Mothers
COVID-19 Case Series: Pregnancy and Infant Outcomes
Infants Born to Mothers with COVID-19 Have Detectable Levels of Antibodies

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site